CytoReason

Company Overview

Snapshot

Founded in September 2016 by Prof. Shai, Elina Starosvetsky, Shai Shen-Orr, David Harel, Ksenya Kveler, and Yuval Kalugny, CytoReason operates with 51–200 employees. The company has raised $132 million across 6 funding rounds from 6 investors, with OurCrowd being a notable lead investor in multiple rounds. In July 2024, CytoReason secured an $80 million financing round, with participation from investors including OurCrowd and Nvidia, to expand its AI-based computational disease models.

Business overview

CytoReason is a technology company that develops a computational model of the human body to simulate human diseases at a cellular level. Its proprietary database and AI-led platform enable pharmaceutical and biotechnology companies to make data-driven decisions, reducing the need for animal trials and making human trials more focused and accurate. The company's technology is utilized by top pharmaceutical firms globally to identify new opportunities, shorten trial phases, reduce development costs, and increase the likelihood of drug approval, serving the Health Tech & Life Sciences sector.

Strategic signal

In January 2026, CytoReason unveiled LINA, an AI agent accelerated by NVIDIA, at the JP Morgan Healthcare Conference. LINA is designed to support pharmaceutical R&D by leveraging CytoReason's AI disease models and NVIDIA NIM microservices to interpret complex biological data. This launch signals CytoReason's commitment to advancing biopharma decision-making processes, enhancing the speed, accuracy, and transparency of R&D, and solidifying its position as an innovator in AI-powered drug discovery.

Company Intelligence Q&A

What significant product did CytoReason unveil in January 2026?

In January 2026, CytoReason unveiled LINA, an AI agent accelerated by NVIDIA, at the JP Morgan Healthcare Conference. LINA is designed to support pharmaceutical research and development by utilizing CytoReason's AI disease models and NVIDIA NIM microservices to interpret complex biological data.

What was the outcome of CytoReason's collaboration expansion with Sanofi in January 2026?

In January 2026, CytoReason expanded its collaboration with Sanofi for the third time, a multi-year agreement valued at up to $16 million. This partnership focuses on advancing AI-driven drug discovery by leveraging CytoReason's computational disease modeling technology to extract insights from molecular and clinical data.

Which investors participated in CytoReason's $80 million financing round in July 2024?

In July 2024, CytoReason completed an $80 million financing round with participation from investors including OurCrowd and Nvidia The funds are intended to expand the application of its computational disease models, grow its proprietary data, and establish a new office in Cambridge, Massachusetts.

What was the outcome of the collaboration between Poolbeg Pharma and CytoReason in June 2023?

In June 2023, Poolbeg Pharma announced a breakthrough in its influenza AI program with CytoReason. Their collaboration led to the identification of several novel drug targets for treating influenza by analyzing disease progression data from human challenge trials using CytoReason's AI-led platform.

What was the nature of CytoReason's extended cooperation with Sanofi in January 2023?

In January 2023, CytoReason extended its cooperation with French drugmaker Sanofi to use its computational disease model platform. This collaboration aims to predict responses to drugs for patients with inflammatory bowel disease (IBD) and provide insights for drug development in this area.